{
  "openalex_id": "W2952881773",
  "doi": "https://doi.org/10.1002/hon.74_2629",
  "title": "EFFICACY AND SAFETY OF OBINUTUZUMAB + LENALIDOMIDE + ATEZOLIZUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA: PRIMARY ANALYSIS OF A PHASE 1B/2 TRIAL",
  "abstract": "Introduction: In the phase 2 GALEN study, induction and maintenance with obinutuzumab (GA101; G) plus lenalidomide (LEN) demonstrated favourable activity and tolerable safety in patients (pts) with relapsed/refractory (R/R) follicular lymphoma (FL). G plus atezolizumab (atezo) has also demonstrated activity in this setting. We present primary efficacy and safety data from a phase 1b/2 study (BO29562; NCT02631577) evaluating induction and maintenance with G-LEN-atezo in pts with R/R FL. Methods: BO29562 is an open-label, multicentre study. All pts had received ≥1 prior anti-CD20-containing chemoimmunotherapy regimen. An initial 3+3 dose-escalation phase to define the phase 2 LEN dose was followed by an expansion phase. Pts received induction with six 28-day cycles (C) of: G 1000 mg IV on day (D) 1, 8, and 15 of C1 and D1 of C2–6; LEN 15/20 mg (dose escalation) or 20 mg (expansion) PO on D1–21 of C1–6; and atezo 840 mg IV on D1 and 15 of C2–6. Responders received maintenance for 24 months (G 1000 mg D1 every 2 months; LEN 10 mg D1–21 months 1–12; atezo 840 mg D1–2 every month). The primary endpoint was complete response (CR) by PET-CT assessed by Independent Review Committee (IRC; modified Lugano 2014 criteria) at end of induction (EOI). Minimal residual disease (MRD) was evaluated at EOI (10-5 sensitivity) using the Adaptive ImmunoSEQ® NGS platform (v2). Results: At the time of the primary analysis (23 October 2018), 38 pts (LEN 15 mg, n=4; 20 mg, n=34) had enrolled and entered induction. Baseline characteristics were: median age, 61.5 years; male, 50.0%; Ann Arbor Stage III–IV, 78.9%; FLIPI high-risk (≥3), 26.3%; bulky disease (≥7cm), 15.8%; ≥2 prior lines of therapy, 47.4%; refractory to last line of prior regimen, 44.7%; and refractory to last line of anti-CD20 treatment, 28.9%. In the primary efficacy population (LEN 20 mg, n=32), CR rate at EOI was 71.9% (double-refractory pts [n=12], 66.7%). Most pts who received maintenance had durable clinical responses (median duration of response not yet reached [n=32]; Figure). At baseline, 22/28 MRD-evaluable pts had a circulating clone detected. Of these, 21 were MRD-evaluable at EOI; 16 (76.2%) were MRD-negative (CR, n=15; partial response, n=1). The proportion of pts receiving >90% dose intensity during induction (n=34) and maintenance (n=27), respectively, was: G, 91.2% and 100%; LEN, 76.5% and 70.4%; and atezo, 71.9% and 85.2%. All treated pts had ≥1 adverse event (AE), 28 (73.6%) pts had a grade 3–4 AE, 12 (31.6%) had a serious AE, and 9 (23.7%) had an AE that led to discontinuation of any drug (induction, n=6; maintenance, n=3). Conclusions: CR rate at EOI for the chemo-free regimen G-LEN-atezo is comparable with currently available treatment options in this indication and higher than with historical controls, with durable activity. The overall safety and tolerability profile is consistent with the known profiles for the individual drugs and for G-LEN. Keywords: follicular lymphoma (FL); lenalidomide; obinutuzumab. Disclosures: Morschhauser, F: Consultant Advisory Role: Gilead; Honoraria: Celgene, Roche, Janssen, Bristol-Myers Squibb, Servier, Epizyme. Ghosh, N: Consultant Advisory Role: Seattle Genetics, Janssen, PCYC, Gilead/Kite, Spectrum, BMS, AbbVie, TG Therapeutics, Celgene/Juno; Research Funding: Genentech/Roche, Janssen, PCYC, TG Therapeutics, Seattle Genetics, Juno Therapeutics. Lossos, I: Consultant Advisory Role: Seattle Genetics, Janssen Scientific. Palomba, M: Consultant Advisory Role: Merck, Pharmacyclics; Stock Ownership: Seres; Honoraria: Flagship Ventures, Novartis, Evelo, Seres, Jazz Pharmaceuticals, Therakos, Amgen, Merck; Other Remuneration: Seres, Juno. Mehta, A: Consultant Advisory Role: Spectrum, Celgene, Kite, BMS; Research Funding: Incyte, Roche, Merck, BMS, Epizyme, Seattle Genetics, Kite, Forty Seven Inc, Takeda, Rhizen, Juno; Other Remuneration: Speakers’ Bureau: Astra Zeneca, Kite, Spectrum, Kyowa Kirin, Seattle Genetics. Casasnovas, O: Consultant Advisory Role: Roche, Takeda, BMS, Merck, Gilead, Janssen; Honoraria: Roche, Takeda, BMS, Merck, Gilead, Janssen; Research Funding: Roche, Takeda, Gilead, Abbvie; Other Remuneration: Roche, Takeda, Janssen. Stevens, D: Employment Leadership Position: Norton Healthcare. Chitra, S: Employment Leadership Position: Genentech. Knapp, A: Employment Leadership Position: F. Hoffman-La Roche Ltd. Nielsen, T: Employment Leadership Position: Roche; Stock Ownership: Roche. Oestergaard, M: Employment Leadership Position: Hoffmann-La Roche, Novo Nordisk. Wenger, M: Employment Leadership Position: F. Hoffmann-La Roche Ltd.; Stock Ownership: F. Hoffmann-La Roche Ltd. Salles, G: Consultant Advisory Role: Abbvie, Celgene, Gilead, Epizyme, Janssen, Karyopharm, Kite, Merck, Morphosys, Novartis, Roche, Servier, Takeda; Honoraria: Abbvie, Amgen, BMS, Celgene, Gilead, Epizyme, Janssen, Karyopharm, Kite, Merck, Morphosys, Novartis, Roche, Servier, Takeda.",
  "authors": [
    {
      "display_name": "Franck Morschhauser",
      "id": "A5051605599",
      "orcid": "https://orcid.org/0000-0002-3714-9824",
      "institutions": [
        {
          "id": "I3018718406",
          "display_name": "Centre Hospitalier Universitaire de Lille",
          "country_code": "FR",
          "type": "healthcare"
        }
      ],
      "is_corresponding": false,
      "raw_author_name": "F. Morschhauser"
    },
    {
      "display_name": "Nilanjan Ghosh",
      "id": "A5074766331",
      "orcid": "https://orcid.org/0000-0002-3848-6136",
      "institutions": [
        {
          "id": "I4210100342",
          "display_name": "Levine Cancer Institute",
          "country_code": "US",
          "type": "healthcare"
        }
      ],
      "is_corresponding": false,
      "raw_author_name": "N. Ghosh"
    },
    {
      "display_name": "Izidore S. Lossos",
      "id": "A5049069261",
      "orcid": "https://orcid.org/0000-0002-9346-9013",
      "institutions": [
        {
          "id": "I145608581",
          "display_name": "University of Miami",
          "country_code": "US",
          "type": "funder"
        }
      ],
      "is_corresponding": false,
      "raw_author_name": "I. Lossos"
    },
    {
      "display_name": "M. Lia Palomba",
      "id": "A5052659722",
      "orcid": "https://orcid.org/0000-0001-5099-9156",
      "institutions": [
        {
          "id": "I1334819555",
          "display_name": "Memorial Sloan Kettering Cancer Center",
          "country_code": "US",
          "type": "healthcare"
        }
      ],
      "is_corresponding": false,
      "raw_author_name": "M.L. Palomba"
    },
    {
      "display_name": "Amitkumar Mehta",
      "id": "A5030631799",
      "orcid": "https://orcid.org/0000-0003-0537-4207",
      "institutions": [
        {
          "id": "I32389192",
          "display_name": "University of Alabama at Birmingham",
          "country_code": "US",
          "type": "funder"
        }
      ],
      "is_corresponding": false,
      "raw_author_name": "A. Mehta"
    },
    {
      "display_name": "Olivier Casasnovas",
      "id": "A5062305482",
      "orcid": "https://orcid.org/0000-0002-1156-8983",
      "institutions": [],
      "is_corresponding": false,
      "raw_author_name": "O. Casasnovas"
    },
    {
      "display_name": "Don A. Stevens",
      "id": "A5030896087",
      "orcid": null,
      "institutions": [
        {
          "id": "I202709704",
          "display_name": "Norton Healthcare",
          "country_code": "US",
          "type": "healthcare"
        }
      ],
      "is_corresponding": false,
      "raw_author_name": "D. Stevens"
    },
    {
      "display_name": "Surya Chitra",
      "id": "A5062874736",
      "orcid": "https://orcid.org/0000-0002-5682-9200",
      "institutions": [
        {
          "id": "I118019719",
          "display_name": "Roche (Switzerland)",
          "country_code": "CH",
          "type": "funder"
        }
      ],
      "is_corresponding": false,
      "raw_author_name": "S. Chitra"
    },
    {
      "display_name": "Andrea Knapp",
      "id": "A5044218901",
      "orcid": null,
      "institutions": [
        {
          "id": "I118019719",
          "display_name": "Roche (Switzerland)",
          "country_code": "CH",
          "type": "funder"
        }
      ],
      "is_corresponding": false,
      "raw_author_name": "A. Knapp"
    },
    {
      "display_name": "Tina Nielsen",
      "id": "A5112481640",
      "orcid": null,
      "institutions": [
        {
          "id": "I118019719",
          "display_name": "Roche (Switzerland)",
          "country_code": "CH",
          "type": "funder"
        }
      ],
      "is_corresponding": false,
      "raw_author_name": "T. Nielsen"
    },
    {
      "display_name": "Mikkel Z. Oestergaard",
      "id": "A5108646496",
      "orcid": null,
      "institutions": [
        {
          "id": "I118019719",
          "display_name": "Roche (Switzerland)",
          "country_code": "CH",
          "type": "funder"
        }
      ],
      "is_corresponding": false,
      "raw_author_name": "M. Oestergaard"
    },
    {
      "display_name": "Michael Wenger",
      "id": "A5080563975",
      "orcid": null,
      "institutions": [
        {
          "id": "I118019719",
          "display_name": "Roche (Switzerland)",
          "country_code": "CH",
          "type": "funder"
        }
      ],
      "is_corresponding": false,
      "raw_author_name": "M. Wenger"
    },
    {
      "display_name": "Gilles Salles",
      "id": "A5086354986",
      "orcid": "https://orcid.org/0000-0002-9541-8666",
      "institutions": [
        {
          "id": "I100532134",
          "display_name": "Université Claude Bernard Lyon 1",
          "country_code": "FR",
          "type": "funder"
        },
        {
          "id": "I4210100596",
          "display_name": "Hospices Civils de Lyon",
          "country_code": "FR",
          "type": "healthcare"
        }
      ],
      "is_corresponding": false,
      "raw_author_name": "G. Salles"
    }
  ],
  "publication_year": 2019,
  "publication_date": "2019-06-01",
  "type": "article",
  "cited_by_count": 10,
  "is_retracted": false,
  "is_paratext": false,
  "language": "en",
  "source": {
    "id": "S23714410",
    "display_name": "Hematological Oncology",
    "issn_l": "0278-0232",
    "issn": [
      "0278-0232",
      "1099-1069"
    ],
    "type": "journal",
    "host_organization": "https://openalex.org/P4310320595"
  },
  "volume": "37",
  "issue": "S2",
  "first_page": "113",
  "last_page": "114",
  "open_access": {
    "is_oa": false,
    "oa_status": "closed",
    "oa_url": null,
    "any_repository_has_fulltext": false
  },
  "concepts": [
    {
      "id": "C71924100",
      "display_name": "Medicine",
      "level": 0,
      "score": 0.80413777
    },
    {
      "id": "C2775949291",
      "display_name": "Atezolizumab",
      "level": 5,
      "score": 0.7145263
    },
    {
      "id": "C2777607594",
      "display_name": "Obinutuzumab",
      "level": 4,
      "score": 0.7074507
    },
    {
      "id": "C2776063141",
      "display_name": "Lenalidomide",
      "level": 3,
      "score": 0.6878225
    },
    {
      "id": "C2777058707",
      "display_name": "Follicular lymphoma",
      "level": 3,
      "score": 0.56854403
    },
    {
      "id": "C126322002",
      "display_name": "Internal medicine",
      "level": 1,
      "score": 0.5630821
    },
    {
      "id": "C143998085",
      "display_name": "Oncology",
      "level": 1,
      "score": 0.46165618
    },
    {
      "id": "C31760486",
      "display_name": "Phases of clinical research",
      "level": 3,
      "score": 0.45033485
    },
    {
      "id": "C2781413609",
      "display_name": "Regimen",
      "level": 2,
      "score": 0.44120014
    },
    {
      "id": "C90924648",
      "display_name": "Gastroenterology",
      "level": 1,
      "score": 0.34959757
    },
    {
      "id": "C2780653079",
      "display_name": "Rituximab",
      "level": 3,
      "score": 0.33179137
    },
    {
      "id": "C535046627",
      "display_name": "Clinical trial",
      "level": 2,
      "score": 0.24216172
    },
    {
      "id": "C2779338263",
      "display_name": "Lymphoma",
      "level": 2,
      "score": 0.22705698
    },
    {
      "id": "C121608353",
      "display_name": "Cancer",
      "level": 2,
      "score": 0.20017704
    },
    {
      "id": "C2776364478",
      "display_name": "Multiple myeloma",
      "level": 2,
      "score": 0.19963211
    },
    {
      "id": "C2777701055",
      "display_name": "Immunotherapy",
      "level": 3,
      "score": 0.10996953
    },
    {
      "id": "C2780057760",
      "display_name": "Pembrolizumab",
      "level": 4,
      "score": 0.0
    }
  ],
  "topics": [
    {
      "id": "T10185",
      "display_name": "Lymphoma Diagnosis and Treatment",
      "score": 0.9996
    },
    {
      "id": "T11016",
      "display_name": "Monoclonal and Polyclonal Antibodies Research",
      "score": 0.9993
    },
    {
      "id": "T11157",
      "display_name": "Chronic Lymphocytic Leukemia Research",
      "score": 0.9971
    }
  ],
  "created_date": null,
  "updated_date": null,
  "indexed_in": [],
  "landing_page_url": "https://doi.org/10.1002/hon.74_2629",
  "pdf_url": null,
  "retrieved_date": "2025-07-30T14:45:06.751392",
  "source_database": "OpenAlex"
}